Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Chest. 2021 Jan;159(1):e7-e11. doi: 10.1016/j.chest.2020.09.077. Epub 2020 Sep 12.
Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cytokine storm resistant to multiple anti-cytokine therapies, but eventually responsive to etoposide. Thus, etoposide may have a role as salvage therapy in treatment of cytokine storm in COVID-19. To our knowledge, this is the first reported case of use of etoposide in COVID-19.
2019 年冠状病毒病(COVID-19)由于缺乏有效的治疗方法而导致了大量的发病率和死亡率。正在研究的治疗策略针对的是过度活跃的细胞因子反应,采用抗细胞因子或免疫调节剂治疗。我们报告了一例独特的严重细胞因子风暴病例,该病例对多种抗细胞因子治疗具有抗性,但最终对依托泊苷有反应。因此,依托泊苷在 COVID-19 细胞因子风暴的治疗中可能具有挽救治疗的作用。据我们所知,这是首例报告的 COVID-19 中使用依托泊苷的病例。